Gen ฤฐlaรง ve Saฤlฤฑk รrรผnleri (GENIL), SPK’nฤฑn II-17.1 sayฤฑlฤฑ Kurumsal Yรถnetim Tebliฤi’nin 10. maddesi kapsamฤฑnda 2025 yฤฑlฤฑ gerรงekleลmeleri ve 2026 yฤฑlฤฑ รถngรถrรผlerini deฤerlendirdi.
Deฤerlendirme sonucunda, iliลkili taraf Salutem Ecza Deposu Med. Ltd. ลti. ile 2026 yฤฑlฤฑnda gerรงekleลtirilmesi รถngรถrรผlen yaygฤฑn ve sรผreklilik arz eden satฤฑล iลlemlerinin tutarฤฑnฤฑn, kamuya aรงฤฑklanan son yฤฑllฤฑk finansal tablolardaki hasฤฑlat tutarฤฑnฤฑn %10’unu aลacaฤฤฑ รถngรถrรผldรผ.
Hazฤฑrlanan Yaygฤฑn ve Sรผreklilik Arz Eden ฤฐliลkili Taraf ฤฐลlemleri Raporu’na gรถre, Salutem Ecza Deposu ile yapฤฑlmasฤฑ planlanan ilaรง satฤฑm iลlemlerinde uygulanan fiyat, ลartlar ve kรขr paylaลฤฑm esaslarฤฑnฤฑn emsallere uygun olduฤu, iliลkili taraf olmayan รผรงรผncรผ kiลilerle yapฤฑlan iลlemlerle karลฤฑlaลtฤฑrฤฑldฤฑฤฤฑnda piyasa koลullarฤฑ รงerรงevesinde adil ve makul olduฤu sonucuna varฤฑldฤฑ.
| ฤฐliลkili Taraf ฤฐลlemleri | |
| Yapฤฑlan Aรงฤฑklama Gรผncelleme mi? | Hayฤฑr (No) |
| Yapฤฑlan Aรงฤฑklama Dรผzeltme mi? | Hayฤฑr (No) |
| Konuya ฤฐliลkin Daha รnce Yapฤฑlan Aรงฤฑklamanฤฑn Tarihi | – |
| Yapฤฑlan Aรงฤฑklama Ertelenmiล Bir Aรงฤฑklama mฤฑ? | Hayฤฑr (No) |
| Bildirim ฤฐรงeriฤi | |
| Aรงฤฑklamalar | |
Sermaye Piyasasฤฑ Kurulu'nun II-17.1 sayฤฑlฤฑ Kurumsal Yรถnetim Tebliฤi'nin "Yaygฤฑn ve Sรผreklilik Arz Eden ฤฐลlemler" baลlฤฑklฤฑ 10. maddesi uyarฤฑnca; ลirketimizin 2025 yฤฑlฤฑ gerรงekleลmeleri ve 2026 yฤฑlฤฑ รถngรถrรผleri deฤerlendirilmiลtir. Yapฤฑlan deฤerlendirmeler sonucunda, iliลkili tarafฤฑmฤฑz Salutem Ecza Deposu Med. Ltd. ลti. ile 2026 yฤฑlฤฑ iรงerisinde gerรงekleลtirilmesi รถngรถrรผlen yaygฤฑn ve sรผreklilik arz eden satฤฑล iลlemlerinin tutarฤฑnฤฑn, kamuya aรงฤฑklanan son yฤฑllฤฑk finansal tablolarฤฑmฤฑzdaki hasฤฑlat tutarฤฑnฤฑn %10'unu aลacaฤฤฑ รถngรถrรผlmรผลtรผr. Bu kapsamda hazฤฑrlanan Yaygฤฑn ve Sรผreklilik Arz Eden ฤฐliลkili Taraf ฤฐลlemleri Raporu doฤrultusunda; Salutem Ecza Deposu Med. Ltd. ลti. ile yapฤฑlmasฤฑ planlanan ilaรง satฤฑm iลlemlerinde uygulanan fiyat, ลartlar ve kรขr paylaลฤฑm esaslarฤฑnฤฑn emsallere uygun olduฤu, iliลkili taraf olmayan รผรงรผncรผ kiลilerle yapฤฑlan iลlemlerle karลฤฑlaลtฤฑrฤฑldฤฑฤฤฑnda piyasa koลullarฤฑ รงerรงevesinde adil ve makul olduฤu sonucuna varฤฑlmฤฑลtฤฑr. Pursuant to Article 10 of the Capital Markets Board's Communiquรฉ on Corporate Governance (II-17.1), titled "Transactions on a Continuous and Recurring Basis," the Company's actual transactions for 2025 and projections for 2026 have been evaluated. As a result of the evaluation, it has been anticipated that the amount of the sales transactions expected to be carried out on a continuous and recurring basis with our related party, Salutem Ecza Deposu Med. Ltd. ลti., during 2026 will exceed 10% of the revenue reported in our latest publicly disclosed annual financial statements. Accordingly, based on the Report on Transactions with Related Parties on a Continuous and Recurring Basis prepared in this regard, it has been concluded that the prices, terms and profit-sharing principles applied to the planned sales of pharmaceutical products with Salutem Ecza Deposu Med. Ltd. ลti. are in line with market terms and conditions and are fair and reasonable when compared with transactions conducted with unrelated third parties. | |
